Home / Research library / YK-11
YK-11: molecular data, studies & sources
YK-11 is catalogued here as a research compound. This profile brings together the molecular source record, selected indexed publications and available supplier comparisons. Evidence for a named substance does not authenticate a commercial product.
Compiled by PeptideTech Editors · Sources checked · Selected bibliography, not a systematic review
Molecular formula, weight & structure
- Molecular formula (MF)
- C25H34O6
- Molecular weight (MW)
- 430.5 g/mol
- PubChem compound ID
- 119058028
- Record title
- YK-11
Values describe the selected PubChem molecular entity. Counterions, salt forms, hydration and sequence changes can alter the supplied material. Confirm the exact identity against the supplier specification.
Source: PubChem CID 119058028 · retrieved 2026-10-09

Chemical identifiers and source data
- IUPAC name
- methyl (2E)-2-[(8R,9S,10R,13S,14S,17S)-2'-methoxy-2',13-dimethyl-3-oxospiro[1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthrene-17,5'-1,3-dioxolane]-4'-ylidene]acetate
- InChIKey
- KCQHQCDHFVGNMK-PQUNLUOYSA-N
- SMILES
- C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@]24/C(=C\C(=O)OC)/OC(O4)(C)OC)CCC5=CC(=O)CC[C@H]35
Identifiers
- PubChem CID
- 119058028
- CAS Registry Number
- 1370003-76-1via ChemIDplus, EPA DSSTox, FDA GSRS
- FDA UNII
- Z9748J6B0R
- InChIKey
- KCQHQCDHFVGNMK-PQUNLUOYSA-N
- Wikidata
- Q27295178
CAS numbers are published only from ChemIDplus, EPA DSSTox or the FDA Global Substance Registration System; UNII codes are confirmed in FDA GSRS by structure, sequence or exact name. Checked 2026-10-09.
Calculated molecular descriptors
| Monoisotopic (exact) mass | 430.2355 Da |
|---|---|
| Heavy atoms | 31 |
| Hydrogen-bond donors | 0 |
| Hydrogen-bond acceptors | 6 |
| Rotatable bonds | 2 |
| Topological polar surface area | 71.1 Ų |
| Calculated logP (Crippen) | 4.29 |
| Rings | 5 |
| Stereocenters | 7 |
| Formal charge | 0 |
Computed with RDKit from the published SMILES (Crippen logP, topological polar surface area). Calculated descriptors are not measured properties of a supplied batch.
Registered clinical trials
Studies registered on ClinicalTrials.gov that list YK-11 as an intervention. Studies that only measure the molecule as a biomarker, or use it only as a comparator or background arm for another drug, are excluded. A registration describes a planned or completed protocol; it does not report a result. Active studies are listed first.
No registered study naming this compound was matched. This is a documented gap in registry coverage, not proof that no study exists.
Registry check 2026-10-01 · Run this search on ClinicalTrials.gov
Human intervention studies
Selected studies in which participants received YK-11, with their indexed or reviewed study type. Check the original article for the formulation, population and controls. Studies that only measured the molecule, or used it as a comparator, are listed separately below and are not counted as intervention studies.
No human study that administered this compound was retained in this selected bibliography. This is a documented evidence gap in our selection, not proof that no study exists.
Preclinical research, reviews & other publications
Animal studies, laboratory experiments, reviews and other indexed papers answer different questions. A review is secondary evidence; a case report does not estimate how often an outcome occurs.
- Preclinical / laboratory research
Selective androgen receptor modulator, YK11, regulates myogenic differentiation of C2C12 myoblasts by follistatin expression.
Kanno Y, Ota R, Someya K et al. · Biological & pharmaceutical bulletin · 2013
PMID 23995658 · DOI: 10.1248/bpb.b13-00231
- Research publication · design requires review
YK11 induces oxidative stress and mitochondrial dysfunction in hippocampus: The interplay between a selective androgen receptor modulator (SARM) and exercise.
Dahleh MMM, Bortolotto VC, Guerra GP et al. · The Journal of steroid biochemistry and molecular biology · 2023
PMID 37468001 · DOI: 10.1016/j.jsbmb.2023.106364
- Preclinical / laboratory research
Myostatin inhibitor YK11 as a preventative health supplement for bacterial sepsis.
Lee SJ, Gharbi A, Shin JE et al. · Biochemical and biophysical research communications · 2021
PMID 33588136 · DOI: 10.1016/j.bbrc.2021.01.030
- Preclinical / laboratory research
Selective Androgen Receptor Modulator, YK11, Up-Regulates Osteoblastic Proliferation and Differentiation in MC3T3-E1 Cells.
Yatsu T, Kusakabe T, Kato K et al. · Biological & pharmaceutical bulletin · 2018
PMID 29491216 · DOI: 10.1248/bpb.b17-00748
- Research publication · design requires review
Differential DNA-binding and cofactor recruitment are possible determinants of the synthetic steroid YK11-dependent gene expression by androgen receptor in breast cancer MDA-MB 453 cells.
Kanno Y, Saito N, Saito R et al. · Experimental cell research · 2022
PMID 36030969 · DOI: 10.1016/j.yexcr.2022.113333
- Research publication · design requires review
(17α,20E)-17,20-[(1-methoxyethylidene)bis(oxy)]-3-oxo-19-norpregna-4,20-diene-21-carboxylic acid methyl ester (YK11) is a partial agonist of the androgen receptor.
Kanno Y, Hikosaka R, Zhang SY et al. · Biological & pharmaceutical bulletin · 2011
PMID 21372378 · DOI: 10.1248/bpb.34.318
- Research publication · design requires review
Equine metabolism of the selective androgen receptor modulator YK-11 in urine and plasma following oral administration.
Harding C, Viljanto M, Habershon-Butcher J et al. · Drug testing and analysis · 2023
PMID 36519889 · DOI: 10.1002/dta.3425
- Preclinical / laboratory research
YK11 promotes osteogenic differentiation of BMSCs and repair of bone defects.
Wang R, Zhong Y, Du Q et al. · Journal of molecular endocrinology · 2025
PMID 39660819 · DOI: 10.1530/JME-24-0073
YK-11 supplier sources
Scientific sources describe molecules and experiments. The commercial links below identify recorded supplier packages. A publication or chemical database entry does not verify the seller, purity, sterility or contents of a lot. Some links are affiliate links; see our disclosure.
No priced supplier offers are currently available in this catalog view. The research record remains available independently of stock.
Reference sources & further reading
- PubChem compound record 119058028 — chemical identity and structure.
- FDA Global Substance Registration System: UNII Z9748J6B0R — substance identity, names and codes.
The citations above link directly to publication records. Encyclopedia links are background reading and are not used to establish clinical effectiveness.
Search for additional research
These links run searches; their results have not been individually reviewed and can include unrelated compounds.
Research information is not a dosing guide or a recommendation for personal use. Study findings are specific to the formulation, population and methods tested. Read our source and correction policy.
Related research profiles
Andarine (S4)
C19H18F3N3O6
441.4 g/mol · PubChem CID 9824562
5 selected publications · 0 human intervention studies
Cardarine
C21H18F3NO3S2
453.5 g/mol · PubChem CID 9803963
8 selected publications · 0 human intervention studies · 3 registered trials
Small molecule · highest stage: Phase 2
LGD-4033
C14H12F6N2O
338.25 g/mol · PubChem CID 44137686
8 selected publications · 1 human intervention study · 1 registered trial
Small molecule · highest stage: Phase 2
MK-677
C27H36N4O5S
528.7 g/mol · PubChem CID 178024
4 selected publications · 4 human intervention studies · 4 registered trials
Small molecule · highest stage: Phase 2
MK-777 (Acetamoren)
Molecular identity needs further verification
Source verification pending
0 selected publications · 0 human intervention studies
Ostarine
C19H14F3N3O3
389.33 g/mol · ChEMBL CHEMBL1738889
8 selected publications · 0 human intervention studies · 17 registered trials
Small molecule · highest stage: Phase 3